Zacks Investment Research on MSN
IBRX stock jumps on progress in NK cell therapy production
Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 10 Must-Watch Stocks Right Now. ImmunityBio surged by 7.29 percent on Friday to ...
Researchers in Brazil have engineered natural killer cells to better attack blood cancers, showing improved tumour control in ...
ImmunityBio Inc. IBRX shares are up on Friday morning as the company completed its manufacturing engineering programs for its ...
“While recent single-cell multiomics studies and CRISPR screens in murine NK cells have expanded our understanding, actionable genomic targets in primary human NK cells have remained largely ...
Of 7 subtypes identified 10,000 melanoma cells, C4 Melanoma COCO1A was the only to show indications of being more sensitive to natural killer (NK) and T cells. A certain type of melanoma may be more ...
A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ...
French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). The company’s tetraspecific antibody controlled tumors and improved survival in mice and ...
New UAB research uncovers how NFAT helps uterine NK cells support early placenta development, shedding light on pregnancy ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results